|0.2297|| +0.0045 / +2.00%|
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against advanced primary head and neck cancer. It is also developing its pre-clinical Ligand Epitope Antigen Presentation System technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis. CEL-SCI was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
|Geert R. Kersten||CEO, CFO, Treasurer, Director & CAO|
|Patricia B. Prichep||Secretary & Senior Vice President-Operations|
|Eyal Talor||Chief Scientific Officer|
|William Jones||Vice President-Quality Assurance|
|Daniel H. Zimmerman||Senior VP-Research & Cellular Immunology|